1. Introduction {#s0005}
===============

Despite of incredible advances in the diagnosis and treatment of various diseases, the incidence, prevalence, morbidity and mortality resulting from these diseases continue to escalate. Regardless, the wealth of information in internet, latest research trends, and many other health databases and increasing number of drugs available in the market, the progress to reduce medical need and disease burden is low in both developed and under developed countries. For ages, pharmaceutical products have been one of the main therapeutics to the majority of the less privileged population. The potential of the drugs has attracted the attention of the developed world, to tap their benefits to identify better and safe drugs to combat human diseases, while in the poor nations these products continue to provide health benefits to the diversified categories of patients ([@b0025; @b0035]). The combined efforts of all public and private R&Ds worldwide bring around only few drugs directed against completely novel mechanisms successfully to market each year. Most drugs have had some therapeutic benefit, and some had phenomenal impact on mortality and morbidity, such as the anti-tumor agents. However, in many diseases, for e.g. HIV, Diabetes, and Cancer the cure has not been identified yet. The impact of genomics and proteomics is additionally creating an explosion in the number of drug targets. Today's drug therapies are based solely on approximately 500 biological targets, while, in 10 years' time, the number of targets could well reach 10,000. The increasing demand for new small molecules led to the invention of new technologies in the field of Pharmaceutical Sciences. Ever-increasing understanding of trends in pharmaceutical research, the community continues to struggle with finding solutions to identify lead molecules ([@b0065; @b0060]). The present study is focused on an oil rich country of Middle East, the Kingdom of Saudi Arabia. With emerging globalization of science and education, the challenge of education and research needs in Saudi Arabia has opened new frontiers. As it is moving forward in most of the areas of research and setting up many research centers all over the country, majority of Saudi universities' prime interest is at advancing research in individual fields and enhancing the research atmosphere ([@b0010; @b0055]). The greatest breakthrough during recent years is expanding the role of pharmacists in the developing countries ([@b0070]). Saudi Arabia sets as an example of identifying the primary role in clinical pharmacy, drug discovery and research. Hence, pharmaceutical research is at the forefront and one of the strategic priorities in Saudi Arabia. Our main aim is to study and analyze the research output of Saudi Arabia and to identify highly productive institutes and authors.

Few scientometric studies have been published in this area. [@b0050] provide a scientometric analysis of world papers published by 57 countries in 10 major sub-specialities appearing in three leading international journals during the ten year period. [@b0020] analyzed changes in the authorship and characteristics of articles in pharmacy journals during the 20 year period. In the field of bibliometrics of country output in pharmacology only a few studies have been carried out on India([@b0040; @b0005; @b0030]), China ([@b0045]) and Spain ([@b0015]) which deal with different facets of pharmacological research, its growth, global publication share and rank, international collaboration, institutional and authors productivity profile, etc.

1.1. Objectives {#s0010}
---------------

The main objective of present analysis in this paper is to analyze the Saudi Arabian contribution in the pharmaceutical research during the last 10 years from 2001--10 with a view: (i) to study the productivity profile of the world's top 15 most productive countries; (ii) to study the Saudi Arabian research output, citation impact, and international collaboration share and identify the leading collaborating partner countries; (iii) to study the contribution and citation impact of its most productive institutions & authors; (iv) to study the media of communication in most productive journals, and (v) to study the characteristics of highly cited papers.

2. Methodology and source used {#s0015}
==============================

This study was undertaken based on the publication data from Saudi Arabia and also identifies the top 15 most productive countries in the field of pharmaceutical research. Data for the present study were retrieved from the Scopus international multidisciplinary bibliographical database \[<http://www.scopus.com/search/>\] for the last ten years (2001--2010). The search strategy string used to retrieve the main data on research output, institutions, authors and major journals of Saudi Arabia is as follows:

AFFIL(saudi arabia) AND PUBYEAR \> 2000 AND PUBYEAR \< 2011 AND (LIMIT-TO(SUBJAREA,"PHAR"))

AFFIL(saudi arabia) AND PUBYEAR \> 2000 AND PUBYEAR \< 2011 AND (LIMIT-TO(SUBJAREA,"PHAR")) AND (LIMIT-TO(AF-ID, "King Saud University College of Pharmacy"60001933))

AFFIL(saudi arabia) AND PUBYEAR \> 2000 AND PUBYEAR \< 2011 AND (LIMIT-TO(SUBJAREA,"PHAR")) AND (LIMIT-TO(AU-ID, "Abdel-Aziz, Alaa A M" 8605268800))

AFFIL(saudi arabia) AND PUBYEAR \> 2000 AND PUBYEAR \< 2011 AND (LIMIT-TO(SUBJAREA,"PHAR")) AND (LIMIT-TO(EXACTSRCTITLE, "Journal of Pharmaceutical and Biomedical Analysis"))

For citations data, three year, two year and one year citations window has been used for computing average citations per paper from Saudi Arabia during 2001--2008, 2009 and 2010. For searching and calculating the total international collaborative papers, a separate search strategy, which combines Saudi Arabia's collaboration with 140 major countries, was also prepared.

3. Analysis {#s0020}
===========

3.1. Global publication output in pharmaceutical sciences {#s0025}
---------------------------------------------------------

The publication output of the top 15 most productive countries ranges from 1.35% to 24.49% during 2001--10. The largest contribution is made by USA with 24.49% share, followed far behind by China (7.47% share), Japan (7.42% share), U.K (6.49% share), Germany (5.64% share), India (5.37% share), Italy, France, Canada, Spain and South Korea (with publication share varying from 2.34% to 3.91%), Brazil, Netherlands, Australia and Switzerland (with publication share varying from 1.35% to 1.90%). The publication share has increased in China by 5.8%, followed by India (3.57%), Brazil (0.89%), South Korea (0.75%), Italy (0.38%), Australia (0.21%) and Switzerland (0.07%), as against decrease by 1.28% in Japan, followed by Germany (0.39%), U.K (0.36%), Spain (0.35%), France and Netherlands (0.27% each), USA (0.18%) and Canada (0.11%) from 2001--05 to 2006--10. In terms of publication rank, countries which have improved their global rank are China (from 5th to 2nd), India (from 8th to 3rd), Canada (from 10th to 9th), South Korea (from 12th to 11th) and Brazil (from 14th to 12th), in contrast to countries losing their rank such as Japan (from 2nd to 4th), UK (from 3rd to 5th), Germany (from 4th to 6th), France (from 6th to 8th), Spain (from 9th to 10th) and Netherlands (from 11th to 14th) from 2001--05 to 2006--10. For other countries, global publications rank has remained the same during the above mentioned period ([Table 1](#t0005){ref-type="table"}).

3.2. Saudi Arabia's publication output, citation impact and international collaboration {#s0080}
---------------------------------------------------------------------------------------

The research output of Saudi Arabia in pharmaceutical science consists of 1386 papers during 2001--10, which has increased from 111 papers in 2001 to 301 papers in 2010, registering an annual average growth rate of 14.21%. The cumulative research output of Saudi Arabia in pharmaceutical science has increased from 567 papers during 2001--05 to 819 papers during 2006--10, witnessing a growth rate of 44.44%. The global share of Saudi Arabia was only 0.50% during 2001--10. The average citation impact per paper registered for total papers in pharmaceutical science of Saudi Arabia was 3.36, which marginally decreased from 3.38 during 2001--05 to 3.35 during 2006--10 ([Table 2](#t0010){ref-type="table"}).

The international collaborative output of Saudi Arabia in pharmaceutical science consists of 562 papers, constituting 40.55% share of its total publications output during 2001--10. The share of international collaborative output of Saudi Arabia has increased from 32.45% during 2001--05 to 46.15% during 2006--10 ([Table 2](#t0010){ref-type="table"}). Of the total international collaborative papers published by Saudi Arabia in pharmaceutical science with different countries, 15 countries have published 8 or more papers. The largest number of international collaborative papers (247 papers, 43.95% share) of Saudi Arabia is published with Egypt, followed by USA (88 papers, 15.66% share), India (70 papers, 12.46% share), U.K. (40 papers, 7.12% share), Germany and Japan (20 papers, 3.56% share each), Canada (19 papers, 3.38% share), Sudan (16 papers, 2.85% share), etc. The international collaborative share of Saudi Arabia has increased by 11.21% with Egypt, followed by India (8.82%), Pakistan (5.03%), Canada (2.6%), Sweden (2.38%), Japan (0.44%), Sudan (0.19%) and U.K (0.07%), as against decrease by 7.42% by USA, followed by Turkey (5.73%), Kuwait (1.93%), Jordan (1.67%), Belgium (1.66%), Germany (0.36%) and United Arab Emirates (0.04%) from 2001--05 to 2006--10 ([Table 3](#t0015){ref-type="table"}).

3.3. Focus of pharmacological research {#s0030}
--------------------------------------

### 3.3.1.Organs {#s0085}

If we study organ-wise the focus of research, we can get ideas regarding the nature of pharmaceutical research being probed in Saudi Arabia. The maximum focus of pharmaceutical research in Saudi Arabia during 2001--10 has been on liver (with 169 papers), followed by kidney (102 papers), heart (84), muscle (56), stomach (49), skin (48), brain (43), breast (42), eye (16), artery (14), pancreas (12), ear (8), throat (5), genital (4), feet (3) and neck (2).

### 3.3.2. Disease {#s0035}

The maximum output of pharmaceutical research has been reported on cancer (with 149 papers), followed by heart diseases (104 papers), diabetes (61 papers), respiratory infection (26 papers), blood disorders (22), tuberculosis (15), depression (14 papers), HIV/AIDS (10), diarrhea (10), epilepsy (10 papers), pneumonia (9), malaria (9), hepatitis (9 papers), cirrhosis (6), leishmaniasis (6), etc.

### 3.3.3. Pharmacological activity {#s0040}

The largest pharmaceutical activity reported in the literature was on enzyme activity (with 125 papers), followed by anti-oxidant activity (87 papers), anti-neoplastic activity (70 papers), anti-inflammatory activity (54 papers), anti-microbial activity (40 papers), anti-bacterial activity (27 papers), anti-fungal activity (22 papers), analgesic activity (20 papers), anti-viral activity (17 papers), etc.

3.4. Most productive organizations -- contribution and impact {#s0045}
-------------------------------------------------------------

The top 15 most productive Saudi Arabian organizations involved in pharmaceutical research together have published 1336 during 2001--10. The publications profile of these 15 Saudi Arabian organizations along with their research output, citations received and h-index values are presented in [Table 4](#t0020){ref-type="table"}. These 15 organizations together have contributed 96.39% share (with 1336 papers) in the cumulative publications output of Saudi Arabia, with an average of 89.6 papers per organization. The productivity of these organizations varies from 14 to 505 during 2001--10. Four organizations have contributed more than the average productivity of all organizations. These are King Saud University, Coll of Pharmacy with 505 papers, followed by King Saud University, (185 papers), King Faisal Specialist Hosp & Research Centre (170 papers) and King Abdul Aziz University, Jeddah (109 papers). The average citation per paper registered by the total papers of these 15 Saudi Arabian organizations was 3.41 (varying from 1 to 5.21) during 2001--10. Five organizations have registered higher impact than the group average of all organizations. These are King Faisal Specialist Hosp & Reseach Centre with an average citation per paper of 5.21, followed by Taibah University (5.03), King Saud University, Medical Coll (4.79), King Fahd University of Petroleum & Minerals (4.76) and King Khalid University (3.50). The average h-index of all Saudi Arabian organizations was 10.60 (varying from 4 to 27). Six organizations have scored a higher value of h-index than the average value of h-index of all organizations. These are King Saud University, Coll of Pharmacy with h-index value of 27, followed by King Faisal Specialist Hosp & Research Centre (20), King Saud University (16), King Saud University, Medical Coll (14), King Abdulaziz University (12) and King Fahd University of Petroleum & Minerals (11) ([Table 4](#t0020){ref-type="table"}).

3.5. Most productive authors -- contributions and impact {#s0050}
--------------------------------------------------------

As seen in [Table 5](#t0025){ref-type="table"}, it is clear that the top 15 contributors from Saudi Arabia are affiliated to the following organizations: King Saud Univ, Riyadh (12 authors), Al Qaseem University (one author), Armed Forces Hosp, Riyadh (one author) and King Abdulaziz University (one author). The 15 most productive authors have together contributed a total of 419 papers, constituting 30.23% share of the total output of Saudi Arabia and registering an average productivity per author of 27.93. Four authors have contributed more than the average productivity of all authors. They are H.Y. Aboul-Enein with 85 papers, followed by A. Al-Shabanah (43 papers), I.A. Alsarra (36 papers) and F.F. Belal (30 papers). The 419 publications contributed by the top 15 authors have received 1548 citations, registering a citation impact per paper of 3.69 (varying from 1.83 to 7.47). Seven authors have registered higher impact than the average citation impact per paper of all authors. They are A.A.M. Abdel-Aziz with a citation impact per paper of 7.47, followed by B.H. Ali (6.17), S.A. Rostom (6.13), A.A. Al-Majed (4.56), F.S. El-Feraly (4.19) and H.Y. Aboul-Enein (3.82). The top 15 most productive authors have registered an average h-index of 9.06 (varying from 4 to 16). Five authors have registered higher value of h-index than the average value of h-index of all authors. They are H.Y. Aboul-Enein with a h-index value of 16, followed by A. Al-Shabanah (14), A.A. Al-Majed (12), B.H. Ali (11) and F.F. Belal (11). The 15 authors have received an average international collaborative share of 31.98% (varying from 0.0% to 93.75%). Four authors have received higher share than the average share of international collaborative papers of all authors. They are F.S. El-Feraly with internationally collaborative papers share of 93.75%, followed by A.A.M. Abdel-Aziz (73.33%), H.Y. Aboul-Enein (67.06%) and S.A. Rostom (46.67%) \[[Table 5](#t0025){ref-type="table"}\].

3.6. Research communication in high productive journals {#s0055}
-------------------------------------------------------

The 15 most productive domestic and foreign journals publishing Saudi Arabian research papers together contributed 524 papers in pharmaceutical science, which accounted for 37.81% of the total output of Saudi Arabia during 2001--10. The cumulative share of these 15 journals in total publications output of Saudi Arabia in pharmaceutical science has decreased from 45.50% during 2001--05 to 32.48% during 2006--10 ([Table 6](#t0030){ref-type="table"}).

3.7. Highly cited papers {#s0060}
------------------------

There are 19 Saudi Arabian papers, which have received 50 or more citations since their publication till 22 February 2012 ([Table 7](#t0035){ref-type="table"}). These are referred here as high cited papers. Of the 19 high cited papers, 10 have appeared as articles and 9 as reviews. Of the 19 high cited papers, 5 were international (4 bilateral and 1 multilateral) collaborative. Of the 19 high cited papers, 1 paper falls in the citation range of 201--227, 2 papers fall in the citation range of 100--199 and 16 papers fall in the citation range of 50--99. These 19 high cited papers have received 1566 citations, with an average of 82.42 citations per paper and the citation range of these papers varies from 50 to 227. These 19 high cited papers involve 7 Saudi Arabian organizations. Among them, the largest number of papers (6) is contributed by King Saud University, College of Pharmacy, followed by King Faisal Specialist Hosp & Research Center (5 papers), King Abdul-Aziz University (3 papers), King Saud University, Department of Veterinary Medicine (2 papers), King Faisal University, College of Medicine (1 paper), Armed Forces Hospital, Department of Internal Medicine, Riyadh (1 paper) and Taibah University, Department of Clinical Biochemistry (1 paper).

These 19 high cited papers have appeared in 15 journals. Among them, the largest number of papers (2) each of which appeared in Alimentary Pharmacology and Therapeutics, Current Drug Metabolism, European Journal of Medicinal Chemistry and Pharmacological Research and 1 paper each in Bioorganic and Medicinal Chemistry, Chirality, European Journal of Pharmaceutical Sciences, European Journal of Pharmaceutics and Biopharmaceutics, Food and Chemical Toxicology, International Journal of Pharmaceutics, Journal of Ethnopharmacology, Journal of Pharmaceutical and Biomedical Analysis, Medicinal Research Reviews, Phytotherapy Research and Tetrahedron.

4. Summary and results {#s0065}
======================

Saudi Arabia in pharmaceutical research has produced 1386 papers during 2001--10, increasing from 111 papers in 2001 to 301 papers in 2010 and witnessing an annual productivity of 138.6 and annual average growth rate of 14.21%. Its citation impact was 3.36 during 2001--10, which decreased from 3.38 to 3.35 from 2001--05 to 2006--10. The share of its international collaborating papers output, constitute 40.55% of its output, increasing from 32.45% during 2001--05 to 46.15% during 2006--10. The largest number of international collaborative papers (with 43.95% share) of Saudi Arabia comes with Egypt, followed by USA (15.66% share), India (12.46% share), U.K (7.12% share), Germany and Japan (3.56% share each), Canada (3.38% share), Sudan (2.85% share), etc. The maximum focus of pharmaceutical research was on cancer (with 149 papers), followed by heart diseases (104 papers), diabetes (61 papers), respiratory infection (26 papers), blood disorders (22), tuberculosis (15), depression (14 papers), HIV/AIDS (10), diarrhea (10), epilepsy (10 papers), pneumonia (9), malaria (9), hepatitis (9 papers), etc. In terms of pharmacological activity, the largest research was focused on enzyme activity (with 125 papers), followed by anti-oxidant activity (87 papers), anti-neoplastic activity (70 papers), anti-inflammatory activity (54 papers), anti-microbial activity (40 papers), anti-bacterial activity (27 papers), anti-fungal activity (22 papers), analgesic activity (20 papers), anti-viral activity (17 papers), etc. The top 15 most productive Saudi Arabian organizations involved in pharmaceutical research together have published 1336 during 2001--10, accounting for 96.39% share in the cumulative publications output of Saudi Arabia, with an average of 89.6 papers per organizations. The average citation per paper and average h-index registered by the total papers of these 15 Saudi Arabian organizations were 3.41 (varying from 1 to 5.21) and 10.60 (varying from 4 to 27). The 15 most productive authors have together contributed a total of 419 papers (varying from 15 to 85), constituting 30.23% share of the total output of Saudi Arabia and registering an average productivity per author of 27.93. The average citation per paper and average h-index registered by the total papers of these 15 Saudi Arabian authors were 3.69 (varying from 1.83 to 7.47) and 9.06 (varying from 4 to 16). The top 15 journals where Saudi Arabian scientists have published together contributed 524 papers in pharmaceutical science, which accounted for 37.81% of the total output of Saudi Arabia during 2001--10, decreasing from 45.50% during 2001--05 to 32.48% during 2006--10. There are 19 Saudi Arabian papers, which have received 50 or more citations since their publication. These 19 high cited papers have received an average of 82.42 citations per paper and the citation range of these papers varies from 50 to 227. These 19 high cited papers involve 7 Saudi Arabian organizations and have appeared in 15 journals.

5. Conclusion {#s0070}
=============

There is a need to improve the number of publications in order to measure Saudi Arabia's research in pharmaceutical sciences. As most of the universities and major organizations are speeding up in a setting research atmosphere all over country it is obvious, based on fact of Globalization of Research and education, Saudi Arabia will emerge as one of the productive countries in terms of pharmaceutical research. Rigorous efforts are still necessary with respect to research productivity, international collaborations, multi cultured research environment, cutting edge drug discovery and quality research. It is now clear, that the number of research output in terms of publications has seen a tremendous growth in last 2--3 years. We foresee that Saudi Arabia will become the most productive country in the near future.

Peer review under responsibility of King Saud University.

###### 

Publications output, share & rank of top 15 countries in pharmaceutical sciences, 2001--10.

  Country       Publications output   Publications share   Publications rank                                        
  ------------- --------------------- -------------------- ------------------- -------- -------- -------- ---- ---- ----
  USA           68351                 83676                152027              24.59    24.41    24.49    1    1    1
  China         11859                 34529                46388               4.27     10.07    7.47     5    2    2
  Japan         22602                 23466                46068               8.13     6.85     7.42     2    4    3
  UK            18602                 21684                40286               6.69     6.33     6.49     3    5    4
  Germany       16286                 18751                35037               5.86     5.47     5.64     4    6    5
  India         9449                  23897                33346               3.40     6.97     5.37     8    3    6
  Italy         10280                 13992                24272               3.70     4.08     3.91     7    7    7
  France        10510                 12042                22552               3.78     3.51     3.63     6    8    8
  Canada        8298                  9885                 18183               2.99     2.88     2.93     10   9    9
  Spain         8442                  9227                 17669               3.04     2.69     2.85     9    10   10
  South Korea   5356                  9188                 14544               1.93     2.68     2.34     12   11   11
  Brazil        3918                  7879                 11797               1.41     2.30     1.90     14   12   12
  Netherlands   5591                  5950                 11541               2.01     1.74     1.86     11   14   13
  Australia     4823                  6671                 11494               1.74     1.95     1.85     13   13   14
  Switzerland   3629                  4736                 8365                1.31     1.38     1.35     15   15   15
  World         277907                342774               620681              100.00   100.00   100.00             

###### 

Saudi Arabia: Research output, citation impact and international collaborative papers in pharmaceutical science 2001--10.

  =Publication year   Total papers   Total citations   ACPP   International collaborative papers (ICP)   Share of ICP   Total citations (of ICP)   ACPP (of ICP)
  ------------------- -------------- ----------------- ------ ------------------------------------------ -------------- -------------------------- ---------------
  2001                111            315               2.84   25                                         22.52          118                        4.72
  2002                122            416               3.41   34                                         27.87          130                        3.82
  2003                120            396               3.30   49                                         40.83          203                        4.14
  2004                102            340               3.33   41                                         40.20          150                        3.66
  2005                112            449               4.01   35                                         31.25          224                        6.40
  2006                96             470               4.90   21                                         21.88          125                        5.95
  2007                115            590               5.13   36                                         31.30          218                        6.06
  2008                132            524               3.97   57                                         43.18          288                        5.05
  2009                175            560               3.20   78                                         44.57          344                        4.41
  2010                301            600               1.99   186                                        61.79          433                        2.33
  2001--05            567            1916              3.38   184                                        32.45          825                        4.48
  2006--10            819            2744              3.35   378                                        46.15          1408                       3.72
  20001--10           1386           4660              3.36   562                                        40.55          2233                       3.97

###### 

Saudi Arabia: International collaborative papers & share in pharmaceutical science 2001--10.

  Period                 International collaborative publications   Share of international collaborative papers                           
  ---------------------- ------------------------------------------ --------------------------------------------- ----- -------- -------- --------
  Egypt                  67                                         180                                           247   36.41    47.62    43.95
  USA                    38                                         50                                            88    20.65    13.23    15.66
  India                  12                                         58                                            70    6.52     15.34    12.46
  UK                     13                                         27                                            40    7.07     7.14     7.12
  Germany                7                                          13                                            20    3.80     3.44     3.56
  Japan                  6                                          14                                            20    3.26     3.70     3.56
  Canada                 3                                          16                                            19    1.63     4.23     3.38
  Pakistan               0                                          19                                            19    0.00     5.03     3.38
  Sudan                  5                                          11                                            16    2.72     2.91     2.85
  Turkey                 12                                         3                                             15    6.52     0.79     2.67
  Jordan                 6                                          6                                             12    3.26     1.59     2.14
  Belgium                5                                          4                                             9     2.72     1.06     1.60
  United Arab Emirates   3                                          6                                             9     1.63     1.59     1.60
  Sweden                 0                                          9                                             9     0.00     2.38     1.60
  Kuwait                 5                                          3                                             8     2.72     0.79     1.42
  Total                  184                                        378                                           562   100.00   100.00   100.00

###### 

Productivity and citation impact of top 15 Saudi Arabian organizations in pharmaceutical science, 2001--10.

  Name of the Institution                                          TP      TC     ACPP   H-Index   ICP   %ICP    HCP   %HCP
  ---------------------------------------------------------------- ------- ------ ------ --------- ----- ------- ----- ------
  King Saud University, Coll of Pharmacy                           505     1626   3.22   27        160   31.68   0     0
  King Saud University                                             185     580    3.14   16        85    45.95   1     0.54
  King Faisal Specialist Hosp & Reseach Centre                     170     885    5.21   20        82    48.24   1     0.59
  King Abdulaziz University                                        109     351    3.22   12        51    46.79   0     0.00
  King Saud University, Coll of Science                            67      170    2.54   10        16    23.88   0     0.00
  King Faisal University                                           59      96     1.63   8         28    47.46   1     1.69
  King Saud University, Medical Coll                               53      254    4.79   14        11    20.75   0     0.00
  Taibah University                                                37      186    5.03   7         16    43.24   0     0.00
  Riyadh Military Hospital                                         35      82     2.34   7         5     14.29   0     0.00
  King Fahd University of Petroleum & Minerals                     25      119    4.76   11        9     36.00   0     0.00
  King Khalid University                                           24      84     3.50   6         16    66.67   0     0.00
  Al Qasim University                                              21      28     1.33   4         9     42.86   0     0.00
  King Khalid University Hosp                                      17      56     3.29   7         1     5.88    0     0.00
  Um Al Qura University                                            15      15     1.00   4         3     20.00   0     0.00
  Ministry of Health, Saudi Arabia                                 14      21     1.5    6         5     35.7    0     0
  Total                                                            1336    4553   3.41   10.6      497   37.2    3     0.22
  Total Saudi Arabia Output                                        1386                                                
  Share of the Top 14 Organizations in total Saudi Arabia Output   96.39                                               

###### 

Productivity and Citation Impact of Top 15 Saudi Arabian Authors in Pharmaceutical Science, 2001--10.

  S. No   Name                Address                                                   TP      TC     ACPP   H-Index   ICP   \% ICP
  ------- ------------------- --------------------------------------------------------- ------- ------ ------ --------- ----- --------
  1\.     H.Y. Aboul-Enein    King Saud Univ, Coll of Pharm                             85      325    3.82   16        57    67.06
  2\.     A. Al-Shabanah      King Saud Univ, Coll of Pharm                             43      147    3.42   14        1     2.33
  3\.     I.A. Alsarra        King Saud Univ, Coll of Pharm                             36      76     2.11   8         5     13.89
  4\.     F.F.Belal           King Saud Univ, Coll of Pharm                             30      84     2.80   11        9     30.00
  5       A.A. Al-Majed       King Saud Univ, Coll of Pharm                             27      123    4.56   12        0     0.00
  6\.     J.S. Mossa          King Saud Univ, Coll of Pharm                             26      75     2.88   7         3     11.54
  7\.     M.A. Al-Omar        King Saud Univ, Coll of Pharm                             26      81     3.12   8         8     30.77
  8\.     B.H. Ali            Al Qaseem Univ, Dept Vet Med                              23      142    6.17   11        6     26.09
  9\.     H.I. El-Subbagh     King Saud Univ, Coll of Pharm                             23      86     3.74   8         7     30.43
  10\.    F.K. Alanazi        King Saud Univ, Coll of Pharm                             19      50     2.63   5         3     15.79
  11\.    H.A. Khan           Armed Forces Hosp, Riyadh                                 18      33     1.83   4         1     5.56
  12\.    N.S. Barakat        King Saud Univ, Coll of Pharm                             17      55     3.24   6         1     5.88
  13\.    F.S. El-Feraly      King Saud Univ, Coll of Pharm                             16      67     4.19   9         15    93.75
  14\.    S.A. Rostom         King Abdulaziz Univ, Deptt Pharm Chem                     15      92     6.13   9         7     46.67
  15\.    A.A.M. Abdel-Aziz   King Saud Univ, Coll of Pharm                             15      112    7.47   8         11    73.33
                              Total                                                     419     1548   3.69   9.06      134   31.98
                              Total Output of Saudi Arabia                              1386                                  
                              Share of Top 15 Authors in Total Output of Saudi Arabia   30.23                                 

###### 

Profile of top 15 Journals where Saudi Arabian scientists have published in pharmaceutical science, 2001--10.

  S. No.   Name of the journal                                     Number of papers   IF 2010           
  -------- ------------------------------------------------------- ------------------ --------- ------- -------
  1        Saudi Pharmaceutical Journal                            76                 69        145     0.13
  2        Biosciences Biotechnology Research Asia                 6                  37        43      
  3        Journal of Pharmaceutical and Biomedical Analysis       30                 12        42      2.73
  4        European Journal of Medicinal Chemistry                 3                  34        37      3.19
  5        Archiv Der Pharmazie                                    17                 15        32      
  6        Farmaco                                                 28                 0         28      
  7        Scientia Pharmaceutica                                  14                 13        27      
  8        International Journal of Pharmacology                   0                  27        27      
  9        Biomedical Chromatography                               17                 10        27      1.54
  10       Phytotherapy Research                                   15                 7         22      
  11       Pharmacological Research                                20                 2         22      3.61
  12       Food and Chemical Toxicology                            4                  16        20      2.602
  13       Pharmazie                                               16                 4         20      0.869
  14       Journal of Medicinal Plants Research                    0                  17        17      0.879
  15       Journal of Ethnopharmacology                            12                 3         15      2.466
           Total                                                   258                266       524     258
           Total Output of Saudi Arabia                            567                819       1386    567
           Share of top 15 journals in Saudi Arabia Total Output   45.50              32.48     37.81   45.50

###### 

List of highly cited papers by Saudi Arabian authors in pharmaceutical science, 2001--10.

  Authors                                                                             Title                                                                                                                                                                                                                        Source                                                                        No. of Citations
  ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------
  Ali B.H., Blunden G.                                                                Pharmacological and toxicological properties of Nigella sativa                                                                                                                                                               Phytotherapy Research 2003, 17(4), 299--305                                   227
  Ghanem A.                                                                           Trends in lipase-catalyzed asymmetric access to enantiomerically pure/enriched compounds                                                                                                                                     Tetrahedron 2007, 63(8), 1721--54                                             134
  Al-Ghamdi M.S.                                                                      The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa                                                                                                                                                  Journal of Ethnopharmacology 2001, 76(1), 45--48                              122
  Khuroo M.S., Khuroo N.S., Farahat K.L.C., Khuroo Y.S., Sofi A.A., Dahab S.T.        Meta-analysis: Endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding                                                                                                                          Alimentary Pharmacology and Therapeutics 2005, 21(4), 347--361                93
  Ghanem A., Aboul-Enein H.Y.                                                         Application of lipases in kinetic resolution of racemates                                                                                                                                                                    Chirality 2005, 17(1), 1--15                                                  89
  Okarvi S.M.                                                                         Peptide-Based Radiopharmaceuticals: Future Tools for Diagnostic Imaging of Cancers and Other Diseases                                                                                                                        Medicinal Research Reviews 2004, 24(3), 357--97                               87
  El-Kamel A.H.                                                                       In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate                                                                                                                            International Journal of Pharmaceutics 2002, 241(1), 47--55                   86
  Saad S.Y., Najjar T.A., Al-Rikabi A.C.                                              The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats                                                                                                            Pharmacological Research 2001, 43(3), 211--18                                 78
  Rostom S.A.F., Shalaby M.A., El-Demellawy M.A.                                      Polysubstituted pyrazoles, part 5.1. Synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid hydrazide analogs and some derived ring systems. A novel class of potential antitumor and anti-HCV agents   European Journal of Medicinal Chemistry 12 Nov 2003, 38, 959--74              67
  Belal F., Al-Zaagi I.A., Gadkariem E.A., Abounassif M.A.                            A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms                                                                                                      Journal of Pharmaceutical and Biomedical Analysis 2001, 24(3), 335--42        67
  Sanai F.M., Bzeizi K.I.                                                             Systematic review: Tuberculous peritonitis - Presenting features, diagnostic strategies and treatment                                                                                                                        Alimentary Pharmacology and Therapeutics 2005, 22(8), 685--700                65
  El Maghraby G.M., Barry B.W., Williams A.C.                                         Liposomes and skin: From drug delivery to model membranes                                                                                                                                                                    European Journal of Pharmaceutical Sciences 5 April 2008, 34, 203--22         64
  Rostom S.A.F.                                                                       Synthesis and in vitro antitumor evaluation of some indeno\[1,2-c\]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems                                Bioorganic and Medicinal Chemistry 2006, 14(19), 6475--85                     61
  Sheweita S.A., Tilmisany A.K.                                                       Cancer and phase II drug-metabolizing enzymes                                                                                                                                                                                Current Drug Metabolism 2003, 4(1), 45--58                                    59
  Kadi A.A., El-Brollosy N.R., Al-Deeb O.A., Habib E.E., Ibrahim T.M., El-Emam A.A.   Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles                                                European Journal of Medicinal Chemistry 2007, 42(2), 235--42                  56
  Ali B.H.                                                                            Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: Some recent research                                                                                                                               Food and Chemical Toxicology 2003, 41(11), 1447--52                           56
  Al-Majed A.A., Mostafa A.M., Al-Rikabi A.C., Al-Shabanah O.A.                       Protective effects of oral arabic gum administration on gentamicin-induced nephrotoxicity in rats                                                                                                                            Pharmacological Research 2002, 46(5), 445--451                                55
  Sheweita S.A., Tilmisany A.M., Al-Sawaf H.                                          Mechanisms of male infertility: Role of antioxidants                                                                                                                                                                         Current Drug Metabolism 2005, 6(5), 495--501                                  50
  Alsarra I.A., Bosela A.A., Ahmed S.M., Mahrous G.M.                                 Proniosomes as a drug carrier for transdermal delivery of ketorolac                                                                                                                                                          European Journal of Pharmaceutics and Biopharmaceutics 2005, 59(3), 485--90   50
